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Chronic activation of the D156A point mutant of
Channelrhodopsin-2 signals apoptotic cell death: the
good and the bad
Michael Perny1,3,4, Lukas Muri1,3, Heather Dawson2 and Sonja Kleinlogel*,1
Channelrhodopsin-2 (ChR2) has become a celebrated research tool and is considered a promising potential therapeutic for
neurological disorders. While making its way into the clinic, concerns about the safety of chronic ChR2 activation have emerged; in
particular as the high-intensity blue light illumination needed for ChR2 activation may be phototoxic. Here we set out to quantify for
the first time the cytotoxic effects of chronic ChR2 activation. We studied the safety of prolonged illumination on ChR2(D156A)-
expressing humanmelanoma cells as cancer cells are notorious for their resistance to killing. Three days of illumination eradicated
the entire ChR2(D156A)-expressing cell population through mitochondria-mediated apoptosis, whereas blue light activation of
non-expressing control cells did not significantly compromise cell viability. In other words, chronic high-intensity blue light
illumination alone is not phototoxic, but prolonged ChR2 activation induces mitochondria-mediated apoptosis. The results are
alarming for gain-of-function translational neurological studies but open the possibility to optogenetically manipulate the viability
of non-excitable cells, such as cancer cells. In a second set of experiments we therefore evaluated the feasibility to put melanoma
cell proliferation and apoptosis under the control of light by transdermally illuminating in vivo melanoma xenografts expressing
ChR2(D156A). We show clear proof of principle that light treatment inhibits and even reverses tumor growth, rendering ChR2s
potential tools for targeted light-therapy of cancers.
Cell Death and Disease (2016) 7, e2447; doi:10.1038/cddis.2016.351; published online 3 November 2016
In the last decade optogenetics has revolutionized the
neurosciences enabling neuroscientists to link neural network
activity with behavior and disease. Latter in particular fostered
the development of optogenetic treatment protocols for
potential use in the clinic. A channelrhodopsin-2 (ChR2)-
based therapy to recover vision in the blind has recently been
approved for clinical trials (NCT02556736) and optogenetic
deep brain stimulation for motor and mood disorders such as
Parkinson’s and depression are currently under active
investigation. The rapid development of ChR2 as a therapeutic
tool has raised concerns about the safety of the required
chronic high-intensity blue light activation and has spurred the
development of more light-sensitive (CatCh,1 ChR2(D156A),2
Opto-mGluR63) and red-shifted (VChR1,4 ReaChR,5
Chrimson6) ChR2 variants, as longer wavelengths are less
harmful.7 Also the potentially non-physiological activation
mediated by ChR2s through continuous strong depolarization
combined with Ca2+ influx1,8 has raised concerns and
alternative tools have been developed that light-activate the
native signaling pathways of target cells.3,8,9
Here we quantified for the first time the blue light and the
ChR2-induced cytotoxicities. To rigorously probe for the induced
changes in cell viability we used a humanmelanoma cell line, as
cancer cells are renowned for their resistance to killing.10–12 We
chose the light-sensitive slow ChR2(D156A) point mutant2 as
optogenetic actuator and showed that 3 days of continuous
pulsed illumination killed all ChR2(D156A)-expressing mela-
noma cells by mitochondria-induced apoptosis. However,
illumination alone did not have any significant effects on cell
viability, indicating that phototoxicity is not of primary concern, but
instead it appears to be the chronic depolarization, potentially
combined with constant Ca2+ inflow into the cytoplasmmediated
through ChR2(D156A) that cause the cytotoxic effects.
The discovery of light-induced apoptotic signaling in cancer
cells highlights an opportunity for targeted cancer cell therapy.
In a second set of experiments we give proof-of-principle
that optogenetic transdermal light treatment of melanoma
xenografts in mice terminates tumor growth. Sparing healthy
tissue from therapy exposure is a critical challenge in the
treatment of cancer that could be overcome in an optogenetic
therapy by localized photoactivation.
Results
To quantify the potential cytotoxic effects of chronic ChR2
activation we employed the 100-fold more light-sensitive
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D156Amutant of ChR2, which possesses the longest channel
open lifetime so far reported (τoff4150 s), mediating sustained
channel opening under pulsed blue light stimulation.2 Long-
term pulsed illumination is experimentally advantageous
compared to continuous illumination as it does not increase
the sample’s temperature, whichmay have negative effects on
cell viability.
To set high measures for the cytotoxicity tests, we
expressed ChR2(D156A) in the human melanoma cell line
BLM,13 as melanoma is renowned for its resistance
apoptosis.14 To avoid cellular stress as a consequence of
permanent ChR2(D156A) expression and potential activation
by daylight, we generated a doxycycline-inducible transgenic
TetOn-BLM cell line in the text referred to as the ChR2
(D156A)-YFP BLM cell line.
Relative calcium permeability of ChR2(D156A). To test if
the ChR2(D156A) Ca2+ permeability lies within the norm for
ChR2 variants, that is, if ChR2(D156A) presents a good
model for the study, we performed two-electrode voltage-
clamp experiments on Xenopus laevis oocytes as previously
described.1 To compensate for the small single channel
conductance (~ 45 fS) and relatively low Ca2+ permeability
intrinsic to ChR2s,1,15 we raised extracellular Ca2+ to 80 mM.
At negative holding potentials (Vh −120 mV), ChR2(D156A)
activation triggered a large inward current with a biphasic rise
time, characteristic for a fast light-activated Ca2+ entry into
the cytosol and a secondary slower activation of the oocyte’s
endogenous Ca2+-sensitive chloride channels (CaCC).1 To
qualitatively compare ChR2(D156A) Ca2+ transmittance to
ChR2 wild-type and the most Ca2+-permeable variant
CatCh,1 we rapidly removed cytosolic-free Ca2+ after light
activation with the fast Ca2+-chelator BAPTA. BAPTA reduced
the amplitudes of the secondary currents in ChR2(D156A)-
expressing oocytes significantly more (85±5%) than in
ChR2-expressing oocytes (66±7%, Po0.001), but less than
in CatCh-expressing oocytes (96±2%, Po0.001). We there-
fore considered ChR2(D156A) a good representative for
ChR2 variants.
Chronic ChR2(D156A) activation kills human melanoma
cells. Forty-eight hours after addition of doxycycline to the
cell culture medium, the ChR2(D156A)-YFP BLM cell line
showed strong membrane-located YFP fluorescence
(Figure 1a). Whole-cell patch-clamp recordings from ChR2
(D156A)-YFP BLM cells confirmed a typical, long-lasting
light-evoked (473 nm) photocurrent with a current density of
1.4±0.9 pA/pF (N=4, mean±S.D., Figure 1b) that could be
terminated by illumination with a second, red-shifted wave-
length (593 nm).2 The prolonged ChR2(D156A) current
activation upon a brief blue light flash enabled us to use a
pulsed illumination protocol (1 s light on, 10 s light off) for our
subsequent cytotoxicity studies, minimizing secondary light
and heat effects.
For chronic pulsed illumination of ChR2(D156A)-YFP BLM
cells in the cell culture incubator, we designed a battery-
powered LED panel carrying a tray for six-well cell culture
plates (Figure 1c). Exposing doxycycline-induced ChR2
(D156A)-YFP BLM cells for 48 h to pulsed light induced clear
morphological changes and reduced cell viability consistent
with apoptosis, that is, membrane blebbing and the appear-
ance of a rounded morphology (Figure 1d) that eventually
led to death and complete cell detachment after 3 days
(Figure 1e). In contrast, chronic blue light illumination over
3 days in control cells (Ctrl Light) that had not received
preceding doxycycline treatment and therefore did not express
ChR2(D156A)-YFP showed no changes in cell viability
(Figure 1f). This was rather surprising as it disproves the
expected phototoxicity of prolonged high-intensity blue light
illumination. Equally, ChR2(D156A)-YFP expression by
doxycycline induction of ChR2(D156A)-YFP BLM cellswithout
subsequent illumination (Ctrl Dox) had no effect on cell
morphology (Figure 1g). In summary, the prolonged
depolarization combined with an increasing intracellular
Ca2+ load may pose concerns in light of a chronic treatment
using ChR2s.
To visualize cell death and track changes in chromatin
morphology indicative of apoptosis, we stained the nuclei with
Hoechst and propidium iodide (PI),16 latter intercalating into
the late apoptotic and necrotic cells. Treated (doxycycline-
induced and illuminated) ChR2(D156A)-YFPBLMcells clearly
showed different apoptosis-associated stages of chromatin
condensation and fragmentation over the 3-day illumination
period (Figures 1h and i), indicative of efficient optogenetic
induction of controlled cell death, which were not apparent in
Ctrl Light and Ctrl Dox cells.
The percentage of apoptotic cells after 2 and 3 days of
treatment was quantified with flow cytometry using Annexin
V/PI staining. One of the earlier events of apoptosis includes
transfer of phosphatidylserine, which ordinarily resides on the
cytoplasmic surface of themembrane, to the outer cell surface.
Annexin V has high affinity for phosphatidylserine and labels
apoptotic cells. The Annexin V/PI assay clearly showed more
early (Annexin V+/PI−) and late apoptotic (Annexin V+/PI+)
cells in the treated ChR2(D156A)-YFP BLM group (Figure 2a)
compared to the Ctrl Light (Figure 2b) and Ctrl Dox groups
(Figure 2c). The bar graph in Figure 2c quantifies the results,
confirming a significantly higher percentage of early and late
apoptotic cells in the treated ChR2(D156A)-YFP group after
2 days (early apoptotic: 18.7±3.2% (Po0.01 versus Day 3
Ctrl Dox, Po0.05 versus Day 3 Ctrl Light); late apoptotic:
24.6±2.4% (Po0.01 versus Day 3 Ctrl Dox and Ctrl Light)
and 3 days (early apoptotic: 48.2± 1.8% (Po0.0001 versus
Day 3 Ctrl Dox, Po0.001 versus Day 3 Ctrl Light; late
apoptotic: 40.3± 1.7% (Po0.001 versus Day 3 Ctrl Dox and
Ctrl Light) than in the 3 days Ctrl Light (early apoptotic:
2.96±0.42%; late apoptotic: 13.2± 0.87%) andCtrl Dox (early
apoptotic: 3.76± 1.18%; late apoptotic: 2.33± 0.21%) groups.
However, the Ctrl Light group showed also a small but
significant increase in late apoptotic cells compared to the Ctrl
Dox group (Po0.01), indicating some phototoxicity of the light
treatment alone.
Is Ca2+ involved in melanoma cell death?. To test if BLM
melanoma cells were susceptible to apoptosis induction
through sustained depolarization combined with a rise in
cytosolic Ca2+ we compared side-by-side the effects of the
Ca2+ ionophore A23187 and light-activation of ChR2(D156A)
on cultured BLM melanoma cells.
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Twenty-four hours after A23187 treatment we clearly
observed morphological signs of apoptosis in BLM cells
similar to those observed under optogenetic treatment, such
as membrane blebbing, chromatin condensation and cell
detachment (Figures 2d-g). Also, the Annexin V/PI flow
cytometry assay after ionophore treatment gave similar
results to those observed after optogenetic treatment: a
significant increase of early (Annexin V+/PI−: 23.9± 0.3%,
Po0.01) and late (Annexin V+/PI+: 41.2±1.8%, Po0.01)
apoptotic cells compared to the DMSO control group
(early apoptotic: 6.2± 0.1%; late apoptotic: 8.2± 1.9%;
Figures 2h-j).
A clear indicator of mitochondrial overstrain and mitochon-
drial death pathway induction are the loss of the mitochondrial
transmembrane potential (MMP), which can be visualized on a
flow cytometer by the mitochondrial dye CMXRos, accumulat-
ing in healthy mitochondria. Twenty-four hours after ionophore
treatment, a significantly higher percentage of mitochondria
showed a decreased MMP (negative cell population,
69.1± 5.2%; Po0.05) compared to DMSO controls
(4.25± 3.1%), indicative of mitochondrial Ca2+ overstrain
(Figures 3a-c). Analogously, 2 days of ChR2(D156A) light
treatment resulted in a similarly significant decrease in MMP
(65.3± 6.1%) compared to the Ctrl Light (6.3±1.4%; Po0.01)
and Ctrl Dox groups (2.3±0.2%; Po0.01, Figures 3d-f). Loss
of the MMP causes the release of cytochrome c from the
mitochondria, formation of the apoptosome and activation of
caspase-3 (Figure 5).17 We therefore determined the levels of
active caspase-3 in lysates of treated ChR2(D156A)-YFP
BLM cells and ionophore-treated BLM cells. Already
after 1 day of optogenetic treatment we found a significant,
6.6± 0.6-fold upregulation of active caspase-3 relative
to the Ctrl Dox group (Po0.01, Figure 3g). Again, similar
results were observed 24 h after ionophore treatment with
10.6± 0.5-fold elevated caspase-3 levels compared to the
DMSO controls (Po0.01; Figure 3h).
Figure 1 Illumination of ChR2(D156A)-YFP BLM cells induces morphological signs of cell death. (a) Fluorescence image of the ChR2(D156A)-YFP BLM cells 2 days after
induction with 1 μg/ml doxycycline. All cells show a bright, membrane-located fluorescence signal. (b) Whole-cell voltage-clamp recording showing a typical photocurrent evoked
by a 500 ms long 473 nm (blue bar) light pulse. The channel is closed after 5 s with a 3 s long 593 nm (orange bar) light pulse. (c) Custom-designed battery-powered LED panel
for in vitro experiments. (d and e) Continuous light-treatment of doxycycline-induced ChR2(D156A)-YFP BLM cells led to membrane blebbing and rounding up of cells after 2 days
(d) and cell detachment after 3 days (e). Exposure of ChR2(D156A)-YFP BLM cells to light alone, without preceding doxycycline-induction (f, Ctrl Light) or inducing ChR2(D156A)
expression without illumination (g, Ctrl Dox) for 3 days had no effect on cell viability. (h and i) Activating ChR2(D156A) for 2 days induced chromatin condensation and apoptosis.
Late apoptotic cells are labeled by PI (h, red). Higher magnification of the boxed area (i) shows condensed chromatin forming a ring like structure (arrow 1), already fragmented
chromatin forming a necklace-structure (arrow 2) and the final stadium of chromatin collapse (arrow 3). Hoechst33342 stained nuclei are shown in gray. Scale bars 100 μm
(50 μm in I)
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Terminally, apoptosis leads to DNA fragmentation indicative
of cell death. DNA fragmentation was analyzedwith the sub-G1
flow cytometry assay. Twenty-four hours of ionophore treatment
led to the appearance of a significant hypodiploid, apoptotic
sub-G1 cell population (67.8±1.9%, Figure 4a) compared to
the DMSO control (2.5±0.2%, Po0.05; Figures 4b and c).
Similarly, ChR2(D156A) light treatment significantly increased
the amount of cells in the sub-G1 peak compared to the controls
(6.9±1.7% after 2 days, Po0.05 versus Day 3 Ctrl Light and
Ctrl Dox; 11.3±0.9% after 3 days, Po0.01 versus Day 3 Ctrl
Light and Ctrl Dox; Figures 4d-f). Additionally, we observed a
G2/M cell cycle arrest in ChR2(D156A)-YFP BLM cells after
2 days of light treatment, with 42.6±3.1% of cells (Po0.01
versus Day 3 Ctrl Dox and Ctrl Light) arrested in the G2-phase,
which increased to 47.6±1.1% (Po0.0001 versus Day 3 Ctrl
Dox andCtrl Light) over the 3-day illumination period (Figure 4f).
A G2/M arrest followed by selective tumor cell apoptosis has
previously been reported for pharmacological treatment of
breast and prostate cancers.18 Also here the Ctrl Light group
showed a significant increase in G2/M cell cycle arrest
compared to the Ctrl Dox (Po0.0001). Although the effect
was significantly smaller than in the treated group, some
phototoxicity seems to be mediated by light treatment alone.
We explain the lack to detect aG2/Marrest in ionophore-treated
BLM cells by the fact that apoptosis is initiated much faster so
that at the time point of the assay most cells had already died.
The above comparative results show that BLM cells are
susceptible to prolonged depolarization combined with a rise
Figure 2 Ca2+ ionophore and ChR2(D156A) optogenetic light treatment have similar effects on BLM cell viability. (a-c) Flow cytometric quantification of apoptosis using
Annexin-V and propidium iodide (PI). Representative plots after 3 days of treatment with ChR2(D156A)+light (a) or light only (Ctrl Light, b). Q3; early apoptotic population, Q2; late
apoptotic population. (c) Quantification, mean±S.D. from three independent experiments. (d-g) Changes in cell (d, e) and chromatin morphology (f,g) after 24-h treatment with
DMSO and 5 μM Ca2+ ionophore A23187. Ionophore treatment led to cell detachment, membrane blebbing (f; arrow 1) and chromatin condensation (f; arrow 2). Late apoptotic
cells are co-labeled by PI (red), Hoechst33342 stained nuclei are shown in gray, scale bars 100 μm. (h-j) Flow cytometry analysis of apoptotic cells using Annexin-V/PI.
Representative plots after 24 h of treatment with (h) 5 μM ionophore A23187 and (i) DMSO, (j) Quantification, mean± S.D. from two independent experiments. *Po0.05,
**Po0.01, ***Po0.001 and ****Po0.0001
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in cytosolic Ca2+ and that optogenetic treatment induces the
mitochondrial death pathway. They also suggest that the small
phototoxic effects of the light treatment alone induce apoptosis
independent of mitochondria, as there were no differences in
MMP, active caspase-3 levels or sub-G1 cell populations
detected between the Ctrl Light and Ctrl Dox groups. The
Figure 3 Side-by-side comparison of the apoptotic pathways induced by ChR2(D156A) and the Ca2+ ionophore A23187, respectively. (a-f) Flow cytometric analysis of MMP
using CMXRos. Representative plots after 24 h of treatment with (a) 5 μM A23187 and (b) DMSO, (c) Quantification. Representative plots after 2 days of treatment with ChR2
(D156A)+light (d) or light only (Ctrl light, e), (f) Quantification. (g and h) Induction of executor caspase 3 determined by the Ac-DEVD-AMC cleavage assay, (g) optogenetic
induction relative to Ctrl Dox after 1 and 2 days of light activation, (h) ionophore and DMSO induction after 24 h relative to non-treated control cultures. Mean± S.D. from two
independent experiments in (c) and (h) and from three independent experiments in (f) and (g). *Po0.05, **Po0.01. n.s., non-significant
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difference between ionophore and optogenetic treatment lies
in the timeline: while ionophore-induced apoptosis is already
completed after 24 h, optogenetically mediated apoptosis
required 3 days (Figure 5a). The difference can be explained
by the bulk Ca2+-influx over the plasma membrane and thus
large depolarization mediated by the ionophore, which
contrasts the small single channel conductance of ChR2
(D156A).2,15
Figure 5b summarizes the proposed pathway for optoge-
netic apoptosis induction in ChR2(D156A)-YFP BLM cells. In
summary, our results are in good agreement with previous
studies showing that both, depolarization and a rise in
cytosolic Ca2+ play a pro-apoptotic role in human melanoma
cells, upregulating in parallel the mitochondrial death
pathway.19–21
Anti-tumor efficacy of ChR2(D156A) in vivo in a xenograft
mouse model. Such effective killing of melanoma cells by
optogenetic treatment prompted us to test the effects in vivo.
We transplanted ChR2(D156A)-YFP BLM cells into the
subcutaneous spaces of both lower flanks of immune-
compromised nude mice. The transplanted mice were then
randomly allocated to one of three treatment groups: the
‘treated group’ received doxycycline and light treatment
(N=11), the Ctrl Dox group received only doxycycline
treatment (N=5) and the Ctrl Light group received only light
treatment (N=6). When one of the tumors in either flank
reached ~ 5 mm in diameter, the 11-day treatment regime
was immediately and individually started to guarantee a
similar efficacy of illumination, as the light intensity is
attenuated by tumor depth.22,23 ChR2(D156A) expression
was induced in tumors of the ‘treated’ and Ctrl Dox groups by
replacing food pellets with doxycycline (200 mg/kg) contain-
ing pellets. Pulsed (1 s on - 10 s off) blue light illumination for
12 h per day over the 11-day treatment period was achieved
by placing the cages of the ‘treated’ and Ctrl Light groups into
a custom-made LED-lining (Figure 6a). Mice were euthanized
at day 11 of the treatment, tumors collected and pathologi-
cally examined as described below. Tumors of mice that were
fed doxycycline consisted exclusively of yellow fluorescing
Figure 4 Sub-G1 cell cycle assays of ionophore and optogenetic treated BLM cells. (a-c) Representative plots after 24 h of treatment with (a) 5 μM A23187 or (b) DMSO, (c)
Quantification, mean± S.D. from two independent experiments. (d-f) Representative plots after three days of treatment with ChR2(D156A)+light (d) or light only (Ctrl light, e), (f)
Quantification, mean± S.D. from three independent experiments. *Po0.05, **Po0.01 and ****Po0.0001
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Figure 5 Hypothetical apoptotic pathway upon light-activation of ChR2(D156A) in BLM melanoma cells. (a) Schematic time-line of apoptotic events in treated ChR2(D156A)-
YFP BLM cells. (b) Proposed apoptotic pathway and hallmarks of optogenetically induced cell death. Blue light activation of ChR2(D156A) leads to cell depolarization and
potentially to an increase of cytosolic Ca2+, leading to Ca2+ uptake into the mitochondria and the endoplasmatic reticulum (ER). Depolarization may potentiate cytosolic free Ca2+
through ER stress, leading to Ca2+ release from the ER. The sharp rise of cytosolic Ca2+ activates the mitochondrial uniporter MCU, which increases Ca2+ in the mitochondrial
matrix, a stimulus for the induction of the permeability transition (PTP formation) resulting in a decreased mitochondrial membrane potential (MMP) and the release of cytochrome
c (Cyt c). Cyt c activates the ‘apoptosis executor’ caspase 3 via the formation of a complex known as the apoptosome, terminally leading to DNA fragmentation.
Phosphatidylserine is switched to the outer leaflet of the plasma membrane during apoptosis acting as an ‘eat-me’ signal for adjacent phagocytes
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cells, indicative of ChR2(D156A)-YFP expression (Figure 6b).
While tumors displayed rapid and continued growth in both
control groups during the course of treatment, tumor growth
halted in the optogenetically treated group and in some cases
tumor size even decreased (Figures 6c and d). The mean
tumor volume after 11 days of treatment was 368± 71 mm3
in the Ctrl Dox, 380±40 mm3 in the Ctrl Light and 37±9 mm3
in the treated group (mean±S.E.M.), significantly smaller
than that of both control groups (Po0.01, Figure 6c). As the
growth curves of the Ctrl Dox and Ctrl Light groups were
virtually identical, we combined the two control groups in the
subsequent pathological analyses.
Paraffin-embedded tumors were sectioned, which con-
firmed that treated tumors were also in their z-axis extension
much smaller than control tumors after 11 days of treatment
(Figure 7a). For each section, three representative annotation
fields located centrally and peripherally in the tumor with a
width of 300–500 μm and a maximum depth of 200 μm were
scored by two independent observers to whom the identity of
sections was unknown (Figure 7a). To determine the amount
of mitotic and apoptotic nuclei, sections were stained with
hematoxylin and eosin (H&E) and positive cells counted by
trained pathologists (Figure 7b). As the standard determina-
tion of mitosis per high power field is not a true index of mitosis
and varies in tumors due to area differences in cellularity, we
normalized for cellularity by calculating the ratio of mitotic cells
per total cell number in each annotation field before averaging.
As expected, non-treated tissue contained significantly more
Figure 6 Light stimulation inhibited growth of subcutaneous melanoma xenografts in nude mice. (a) LED-illumination cages used for xenograft simulation. (b) In vivo
expression of ChR2(D156A)-YFP after doxycycline induction visualized by green YFP fluorescence. The tumor is clearly delineated and the membrane location of ChR2(D156A)
is evidently visible in the enlarged insert. Scale bar 50 μm. (c) Growth curve of the tumors after doxycycline induction and/or illumination indicated as changes in extrapolated
tumor volume. All experimental mice were injected with inducible BLM cells and the experiment was started when the tumors reached a diameter of 5 mm (here set to 0), by either
inducing ChR2(D156A)-YFP expression with doxycycline (Ctrl Dox, N= 5) or by illumination of the tumor (Ctrl Light, N= 6) or by both (treated, N= 11). Ctrl Dox and Ctrl Light,
since almost identical, were averaged to the ‘combined Ctrl’. (d) Examples of excised tumors on day 11 of the treatment. Left lane: (1) and (2) Ctrl Light, (3) Ctrl Dox, right lane:
examples of treated tumors. Scale bar 5 mm. **Po0.01, ***Po0.001
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mitotic cells (4.8±0.3%, mean± s.e.m.) than treated tumor
tissue (2.4±0.4%,mean± s.e.m.,Po0.001, Figure 7c). As an
estimate of tumor growth dynamics, we then determined the
apoptosis-to-mitosis ratio,24 which was again significantly
elevated in treated tissue (0.59±0.05, mean± s.e.m.) com-
pared to controls (0.34±0.06, mean± s.e.m., Po0.01),
explaining the cessation of tumor growth under optogenetic
treatment (Figure 7c). To relate the pro-apoptotic and anti-
proliferative effects of the in vivo treatment to our in vitro data,
we performed PHH3 (phosphohistone H3)25 and cleaved
caspase-3 immunohistochemistry on additional paraffin sec-
tions. PHH3 is considered an effective marker to visualize the
mitotic index and differentiate between mitotic figures and
apoptotic bodies, as phosphorylation at histone H3 almost
exclusively occurs during mitosis26 and is absent during
apoptosis.27 As expected, PHH3 labeling paralleled themitotic
count, which was significantly increased in non-treated tissue
(14± 2.2%) compared to treated tissue (5.6± 1.5%, Po0.01,
Figures 7c and d). In line with our in vitro data, also caspase-3
was significantly elevated in treated tissue (8.1± 1.0%,
mean± s.e.m.) compared to control tissue (3.0±1.0%,
mean± s.e.m., Po0.01, Figures 7c and d).
Our in vivo results indicate the potential value of a ChR2-
based optogenetic cancer therapy. As illumination of the
xenograft tissue was restricted to daytime in order to comply
with animal ethics, the effects of chronic illumination would
expectedly be enhanced.
Discussion
The majority of recent translational studies mention the
potential phototoxicity of prolonged ChR2 activation in a
clinical setting,3,28 as ChR2s require above human safety
threshold radiation intensities for activation.7 As such cytotoxic
effects have never been quantified, we here mended this gap
Figure 7 Immunohistochemistry on paraffin sections of excised xenograft tumors. (a) Paraffin sections of a control (top) and a treated (bottom) tumor showing the smaller
z-axis extension of the treated tumor and the locations of the annotation fields for scoring. Scale bar 500 μm. (b) Example H&E-stained sections (most superficial 100 μm of tumor
tissue) of treated (top) and control (bottom) tissue, showing the clearly increased apoptosis-to-mitosis ratio in treated tumors. Filled arrows mark apoptoses, open arrows indicate
mitoses. (c) Quantification of scoring. Mean± S.E.M. (d) Examples from immunohistochemically stained control and treated subcutaneous xenograft tissue. Scale bars (c and d)
50 μm. **Po0.01, ***Po0.001
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and chronically illuminated ChR2(D156A)-expressing BLM
melanoma cells. We could clearly show that 3 days of pulsed
light killed all melanoma cells. The cytotoxic effects are
expected to be enhanced in neurons, as cancer cells are
almost resistant to killing. However, at least under the given
illumination conditions, cell death was not primarily mediated
by the suspected blue light phototoxicity but rather by
prolonged membrane depolarization, which had previously
been demonstrated to potentiate apoptosis induction in
melanoma cells.19 Nonetheless, a slight but significant
increase in the amount of apoptotic cells was also observed
in cell culture experiments in the Ctrl Light group
(see Figures 2c and 4f) that may be further enhanced when
wild-type ChR2 is employed, which requires sustained light
activation due to its fast off-kinetics and 100-times higher light
intensities. However, differences in the Ctrl Light and Ctrl Dox
groups were absent in the in vivo xenograft experiments,
suggesting that phototoxicity is low. The similarity of the
sequences of apoptotic events triggered optogenetically and
by the calcium ionophore A23187 confirmed activation of the
mitochondrial death pathway under optogenetic treatment.
Directly light-induced apoptosis on the other hand seems to be
independent of the mitochondrial pathway, as no significant
changes in MMP, active caspase-3 levels or a sub-G1
population were detected in the Ctrl Light group (see
Figures 3f and 4e). Illumination regime, light intensity and
Ca2+ transmittance of the used ChR2 variant all contribute to
the final cytotoxic effect, which is difficult to foresee and to
experimentally determine, as long-term high-intensity illumi-
nation leads to heat production and phototoxicity and Ca2+
per se is a finely tuned second messenger with diverse roles.
Nonetheless, ChR2 variants that had been developed for
improved clinical applicability with increased light response
amplitudes and slowed kinetics will increase the overall cell
depolarization and Ca2+ transmittance, which renders them
potentially more toxic.1,2 Recently developed Opto-GPCRs
that are coupled to native cellular pathways3,9,29,30 and are
1000-fold more light sensitive may therefore present alter-
native safer tools for the treatment of neurological disorders in
human patients.
Skin cancer is a devastating disease with rapidly increasing
incidence.31 Melanoma treatment remains particularly chal-
lenging due to the disease’s frequent relapse mediated by the
cancer cells’ acquired resistance to treatment10–12,32 in terms
of changes in specific apoptosis signaling.12 Although relying
on apoptosis, optogenetic treatment presents a highly
ubiquitous apoptotic stimulus that melanoma cells appear to
be unable to evade by specific pathway accommodations.
We demonstrate in both, melanoma cell culture and
xenografts that melanoma cell viability decreases under
optogenetic light treatment by activating the mitochondrial
death pathway. Expression of ChR2s in cancer cells may thus
be worthwhile to be evaluated as a potential cancer
therapeutic, alone or in combination with existing treatments
to boost their efficacies. A combination with photoactivatable
agents such as light-activated antibodies that harness the
immune system33,34 could be attractive as local photoactiva-
tion adds treatment specificity and spares healthy tissue.
Precise light delivery methods have been developed for
photodynamic cancer therapy, and more recently, for
optogenetics.22 A second level of treatment specificity could
be given by selective expression of ChR2 in cancer cells.
Molecular tools for genetically targeted expression are under
active investigations with some promising genetic tools
arising, such as cancer cell-specific promoters35,36 and
systemically deliverable viruses that efficiently target cancer
cell surface proteins.37–39 The fact that optogenetics induces
controlled apoptotic cell death and not necrosis reduces the
risk of a spreading inflammation adding a third level of
specificity.
In conclusion, the current study demonstrates another
opportunity for the optogenetic toolbox to extend beyond
excitable cells to inhibit cancer cell proliferation.
Materials and Methods
BLM human melanoma cell line. The highly invasive human melanoma
cell line BLM, a subline of the aggressive human melanoma cell line BRO derived
from a biopsy of a malignant human primary melanoma of the skin,13 was obtained
from H. Büning (Center for Molecular Medicine, University of Cologne, Germany).
BLM cells were maintained in 1640 RPMI medium (Sigma-Aldrich, St. Louis, MO,
USA) supplemented with 10% FCS (Biochrom, Berlin, Germany), 100 Units/ml
Penicillin (Sigma-Aldrich), 100 mg/ml Streptomycin (Sigma-Aldrich), 1% Glutamin
(Sigma-Aldrich) and 1% non-essential amino acids (Gibco, Carlsbad, CA, USA) at
37 °C and 5% CO2. The cells were passaged every 3-4 days at a 1:10 ratio using
trypsin/EDTA.
Inducing cell death with ChR2(D156A) and light in pTRE3G-ChR2
(D156A)-YFP BLM cells: On the first day, pTRE3G-ChR2(D156A)-YFP BLM
cells were seeded in six-well plates (TPP) at 8 × 104 cells/well in doxycycline-free
BLM medium. ChR2(D156A)-YFP expression was induced for 2 days with 1 μg/ml
doxycycline (Pfizer, New York, NY, USA), following replacement of medium with
doxycycline-free BLM medium containing 1 μM all-trans retinal. Immediately
afterwards, cells were put on the LED light exposure chamber (see below) at 37 °C
and 5% CO2.Doxycycline and all-trans retinal were replenished every 24 h.
Inducing cell death with the calcium ionophore A23187 in pTRE3G-
ChR2(D156A)-YFP BLM cells: pTRE3G-ChR2(D156A)-YFP BLM cells were
seeded in six-well plates (TPP) at 8 × 104 cells/well in doxycycline-free BLM
medium and incubated at 37 °C and 5% CO2 for two days. Afterwards, the medium
was replaced with doxycycline-free BLM medium containing 5 μM calcium
ionophore A23187 (Sigma-Aldrich).
Molecular biology
pTRE3G-ChR2(D156A)-YFP plasmid construction: The humanized
ChR2(D156A)-YFP gene (hChR2(D156A)-YFP) was cloned into the pTRE3G-
IRES plasmid (Clontech, Mountain View, CA, USA) by using the In-Fusion HD
Cloning Kit (Clontech). The pTRE3G-IRES plasmid was digested with EagI and MluI
and the PCR-amplified hChR2(D156A)-YFP (F: TCTATCGATCGGCCGGATCC
ACCATGGACTACG, R: TAGCCATATGACGCGTCTTTACTTGTACA GCTCGTCC)
inserted.
Generation of inducible pTRE3G-ChR2(D156A)-YFP BLM cell line:
All transfections were performed with the Xfect TM transfection kit (Clontech)
according to the manufacturer’s protocol. First, the wild-type BLM cells were
transfected with the pEF1a-Tet3G plasmid (Tet-On 3G Expression System,
Clontech) and grown under geneticin (1500 μg/ml) selection for 2 weeks. Single
cells were sorted with a FACS Aria III flow cytometer (Becton Dickinson, NJ, USA),
expanded in geneticin selection medium and resistant clones individually probed for
Tet-ON 3G transactivator expression levels by a luciferase assay with the inducible
plasmid pTRE3g-Luc (Tet-On 3G Expression System, Clontech) according to the
manufacturer’s protocol. The highest expressing clone (Tet-on 3G BLM) was
subsequently co-transfected with the pTRE3G-ChR2(D156A)-YFP plasmid and a
linear puromycin selection marker and grown under puromycin (0.75 μg/ml)
selection for 2 weeks. Twenty-four hours before single cell sorting, 1 μg/ml
doxycycline was added to the culture medium in order to induce ChR2(D156A)-YFP
expression. Single cells with high YFP signal were sorted in 96-well plates using the
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FACS Aria III (Becton Dickinson) and the clone with highest ChR2(D156A)-YFP
expression levels qualitatively selected for further experiments (in this manuscript
referred to as ChR2(D156A)-YFP BLM cell line).
Electrophysiology
Two-electrode voltage clamp in Xenopus oocytes: The genes encoding
wild-type ChR2,40 ChR2(D156A)2 and CatCh1 were inserted into the pGEM-HE
vector and expressed in oocytes of X. laevis as described previously.1 Oocytes were
obtained by collagenase treatment after partial ovarectomy and injected with 30 ng
of in vitro-transcribed mRNA (SP6 mMessge mMachine kit, Ambion, Foster City,
CA, USA). After mRNA injection, oocytes were incubated in all-trans retinal (1 μM)
and were kept in ORI buffer (90 mM NaCl, 2 mM KCl, 2 mM CaCl2 and 5 mM
MOPS, pH 7.4) containing 1 mg/ml gentamycin at 18 °C for 2–4 days. In
subsequent two-electrode voltage-clamp experiments, oocyte Ringer contained
80 mM Ca2+ and light activation was achieved with a 75-W xenon arc lamp and a
450± 25 nm band filter, the light of which was coupled into a 1-mm light guide with
an output of ~ 5 mW/mm− 5. To suppress calcium-activated chloride channel
(CaCC) currents, we injected 50 nl of a 20 mM solution of the fast Ca2+-chelator
BAPTA into each oocyte (~1 mM final concentration in the oocyte). The relative
decrease in current amplitude upon BAPTA treatment was taken as a measure for
the qualitative Ca2+ permeability.
Whole-cell patch-clamp recordings in pTRE3G-ChR2(D156A)-YFP
BLM cells: Recordings were performed on an inverted Zeiss Axiovert 35M
microscope. Recordings were made in the whole-cell configuration using
borosilicate glass pipettes (Harvard Apparatus GC150F-10) pulled with a Zeitz
DMZ-Universal puller ranging from 2 to 6 MΩ. The pipette solution contained (in
mM): 123 K-Gluconate, 7 KCl, 1 MgCl2, 5 ATPNa2, 10 EGTA, 10 HEPES (pH 7.4,
KOH). The bath solution contained (in mM): 135 NaCl, 4 KCl, 1 MgCl2, 2 CaCl2, 10
glucose, 10 HEPES (pH 7.4, NaOH). Signals were amplified with an Axopatch 200B
Amplifiter, low pass filtered at 5 kHz and digitized at 50 kHz with an Axon Digidata
1440A. Acquisition and analysis was performed using pClamp software (Molecular
Devices, Biberach, Germany). Membrane voltage was clamped at − 60 mW and
light pulses were supplied by two solid state lasers (Pusch Opto Tech GmbH,
Wettenberg, Germany; λ= 473 nm, λ2= 593.5 nm), which were coupled to a
400 μm optic fiber. Light pulses were applied by a fast computer-controlled shutter
(Uniblitz LS6ZM2, Vincent Associates, Rochester, NY, USA). YFP signals were
observed using 473 nm excitation through a GFP filter set (#31001, Chroma
Technology, Bellows Falls, VT, USA).
In vitro apoptosis assays
Hoechst33342 chromatin staining: Cells were labeled directly in the six-well
plate with 50 μg/ml Hoechst33342 (Sigma-Aldrich) for 5 min at 37 °C and washed
with PBS. PI was added in the volume 5 μg/ml immediately before visualization with
an inverted Zeiss Axiovert 100 Microscope.
Annexin V/propidium iodide flow cytometry assay: Cells were washed
with PBS, dissociated with 200 μl trypsin/EDTA and centrifuged for 6 min at
1000 × g. The pellet was resuspended in 100 μl Annexin V-APC binding buffer
100 mM HEPES, 140 mM NaCl, 25 mM CaCl2 and pH 7.4 in water. One
microliter Annexin V-APC staining solution (Biolegend, San Diego, CA, USA) was
added and the cells incubated for 15 min at room temperature in the dark.
Immediately before measuring with the LSRII SORP flow cytometer (Becton
Dickinson), 400 μl Annexin V binding buffer and 5 μl PI solution (1 mg/ml in PBS,
Sigma-Aldrich) were added. The Annexin V-APC and PI signals were collected on a
logarithmic scale using a 640 nm laser in combination with a 660 nm filter (20 nm
bandwidth) and a 488 nm laser in combination with a 695 nm filter (40 nm
bandwidth), respectively. Analysis was performed with FlowJo software (Version
10.0.7, Treestar Inc. Ashland, OR, USA).
Mitochondrial membrane potential: Cells were washed with PBS, dis-
sociated with 200 μl trypsin/EDTA and centrifuged for 6 min at 1000 × g. The pellet
was resuspended with 300 μl RPMI-1640 (Sigma-Aldrich) containing 100 nM
MitoTracker red CMXRos (Invitrogen, Carlsbad, CA, USA) and incubated at 37 °C
for 1 h. Cells were subsequently centrifuged for 6 min at 1000 × g, resuspended in
300 μl PBS and analyzed with the LSRII SORP flow cytometer (Becton Dickinson).
The CMXRos signal was collected on a logarithmic scale with a 561 nm laser in
combination with a 610 nm filter (20nm bandwidth) and data analyzed using FlowJo
software.
Caspase-3/7 activity: Cells were washed with PBS, dissociated with
200 μl trypsin/EDTA and centrifuged for 6 min at 1000 × g. Harvested cells were
resuspended with 50 μl lysis buffer (0.1% Triton X-100 in PBS, Sigma-Aldrich),
incubated on ice for 10 min and centrifuged for 5 min at 16 000 × g at 4 °C.
The supernatant was carefully transferred into a 96-well plate (Greiner Bio-One,
Frickenhausen, Germany) containing 150 μl HEPES (40 mM HEPES pH 7.5, 20%
Glycerol, 5 mM Dithiothreitol) and 50 μM caspase- 3/7 substrate (Ac-DEVD-AMC).
The reactions were incubated for 30 min at 37 °C in the dark before caspase activity
was measured on a multimode reader (Infinite Pro 200, Tecan; ex: 368/9 nm, em:
475/20 nm). The caspase-3/7 fold induction was determined as the activity ratio of
treated versus non-treated sample.
In vivo xenograft model
Establishment in Swiss nude mice: Experiments were performed on
immune-deficient Swiss Nude (Crl:NU(Ico)-Foxn1nu, Charles River) mice maintained
in a quarantine cupboard equipes with isolated filtered ventilation under a standard
12-h light-dark cycle. All animal experiments were performed in accordance with the
Swiss Federal Animal Protection Act and approved by the animal research
committee of Bern (approval number BE5-14).
The xenograft tumor model was established by subcutaneous injections of
2 × 106 doxycycline-inducible pTRE3G-ChR2(D156A)-YFP BLM cells 100 μl of
DMEM culture medium into both flanks of 4-week-old Swiss Nude mice under
Isofluorane anaesthesia with a 18G needle. Care was taken to create a single
bubble of cells beneath the skin and to avoid spread of the cells. The injection
sites were capped with liquid plaster (OPSITE spray) to avoid infection. The tumor
size was measured on a daily basis using a calliper. When one of the tumors reached
a diameter of ~ 5 mm, the mice were divided randomly into three treatment groups,
(1) receiving doxycycline and light treatment (treated group), (2) receiving only
doxycycline treatment (Ctrl Dox) and (3) receiving only light treatment (Ctrl Light). For
the treated and Ctrl Dox groups, food pellets were replaced by pellets containing
200 mg/kg doxycycline (TD.00502, Teklad 2018 Global Rodent diet, Harlan
Laboratories, Venray, the Netherlands) in order to induce ChR2(D156A)
expression. Concomitantly, the treated and Ctrl Light groups were moved into
LED-lined cages (see Figure 6a and exposed to pulsed (1 s on, 10 s off) blue
light for 11 days. During treatment, tumor size was continuously measured on a daily
basis and tumor volume extrapolated by using the formula V (mm3)= length ×
width2 × 1/2, where L and W represent the largest and the smallest diameters,
respectively.
Immunohistochemistry on excised tumors: Excised tumors were fixed in
formalin for 24 h and embedded in paraffin. Subsequent processing was performed
double-blind: the tissue blocks were randomly numbered for sectioning and
immunohistochemistry and analysis was performed by observers blinded to
treatment. The tumor containing paraffin-blocks were randomly numbered
(11 treated, 11 untreated mice) and sectioned at 2.5 μm by a blinded histologist.
Sections were stained with H&E and antibodies against Ki-67 (rabbit monoclonal
antibody, Thermo Fisher Scientific, Boston, MA, USA; clone SP6; pretreatment
Tris95 C 30′; dilution: 1:200), phosphohistone H3 (PHH3; rabbit monoclonal
antibody, Cell Signaling, Beverly, MA, USA; clone 5A1E; pretreatment Tris95 C 30′;
dilution: 1:100) and cleaved Caspase 3 (rabbit monoclonal antibody, Cell Signaling,
clone 5A1E; pretreatment: Tris95 C 30′; dilution: 1:100). Immunohistochemistry was
performed on an automated platform (Leica Bond RX, Leica Biosystems, Muttenz,
Switzerland).
Scoring of immunohistochemistry, mitotic figures and apoptotic
bodies: For scoring, all slides were scanned to a digital platform, chronologically
labeled and assessed by a blinded experimenter using Pannoramic viewer
(3D Histech, Budapest, Hungary). The measurement tool was used to create
annotation fields with a width of 300-500 μm and a maximum depth of 200 μm from
the subcutaneous tissue to ensure scoring only in areas which received sufficient
light power for ChR2(D156A) activation (see Figures 6a and c). Light propagation
through the tumor was estimated by values known for blue light attenuation in brain
tissue,23 the known light sensitivity of ChR2(D156A)2 and the assumption that the
tight packaging and strong vascularization of the tumor leads to an additional light
attenuation of approximately 25%. For each section, three annotation fields
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centrally and peripherally in the tumor containing an average of 469± 171 cells
each were scored (visual count, see Figures 6a and c). The percentage of positive
cells was calculated. For immunohistochemical stainings, any staining intensity not
attributable to background was considered positive. On the same platform, the
corresponding areas were selected on H&E-stained slides for counting the
percentage of mitotic figures and apoptotic bodies. Immunohistochemical stainings
were scored by two independent observers and the H&E-stained slides were scored
by a consultant pathologist.
Illumination. A battery powered LED panel to hold a six-well cell culture plate
was custom-designed in order to supply sustained pulsed illumination to ChR2
(D156A)-YFP BLM within the cell incubator (see Figure 1c). The circular 5 mm
LEDs (Conrad, Dietlikon, Schweiz; part number NSPB500AS Sel. wV/W, 470 nm,
11 000 mcd, 15) were arranged to supply consistent illumination 5 mW/mm2 across
the whole cell culture plate.
LED-lining for mouse cages was custom-made by strips of interspersed
high-power LEDs (Digi-Key electronics, Thief River Falls, MN, USA; part number
XPEBLU-L1-R250-00Y01CT-ND). The 30 cm wide LED strips were placed on all four
sides of the mouse cage just above the chaff (see Figure 6a) and consisted of three
rows of single LEDs (475 nm, 33 lm, 130) with distances of 3 cm between LEDs in a
row and the middle row aligned interspersed with the other two rows in order to
achieve balanced illumination intensities throughout the cage. The subcutaneous light
intensity above the tumor was estimated with a spectrophotometer (Thorlabs,
Dortmund, Germany) held behind the skin of a sacrificed mouse and equaled
6.25 mW/mm2 for a mouse located in the center of the cage. Four hundred seventy-
nanometer light was shown to have an attenuance of 0.2 in tumor tissue over a
0.2 mm path length.22 We therefore assumed the light intensity to reach saturating
values for ChR2(D156A) activation to a tumor depth of minimally 5.8 mm2.
Statistical analysis. Statistics was performed either by Excel or Graph Pad
Prism statistics software (version 6.0.). For all normal distributions (verified using
the Kolmogorov-Smirnov test), differences between optogenetically treated and
control groups were analyzed using an unpaired one-tailed Student’s t-test. All
in vitro data (n⩽ 3) was analyzed using an unpaired two-tailed Student’s t-test with
Welch correction, not assuming equal variance. In the figures, different levels
of significance are indicated by * if Po0.05, ** if Po0.01, if *** if Po0.001 and
**** if Po0.0001. In the text, average values are indicated± standard deviation,
unless otherwise indicated.
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